Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.
Online First articles have been peer reviewed, accepted for publication, and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.
Online First articles are copyedited by the science editors and the editorial production team, typeset, and proofread approved by the author before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.
Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections. You may also view the abstract by clicking on the article link.
Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.
Fourth and final issue of GaBI Journal’s fifth volume / Professor Philip D Walson, MD, USA/Germany
Physicians, Hippocrates and biosimilars: applying ancient principles in a modern society / Professor Pekka Kurki, MD, PhD, Finland
Letters to the Editor
Pricing strategies for pharmaceuticals in developing countries: what options do we have? / Nada Moustafa Abdel Rida, Qatar; Professor Mohamed Izham Mohamed Ibrahim, PhD, Qatar
Current overview of biosimilars in Iran / Hamideh Aghajani-Lazarjani, PhD; Fereidoun Mahboudi, PhD, Iran
Naming and labelling of biologicals – the perspective of hospital and retail pharmacists / Professor Philip Schneider, MS, FASHP, USA; Michael S Reilly Esq, USA
Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future / Babar Khan, BPharm, MPH, PhD; Brian Godman, BSc, PhD; Ayesha Babar, BPharm, MPhil; Shahzad Hussain, BPharm, PhD; Sidra Mahmood, PharmD, MSc; Tahir Aqeel, BPharm, MPhil
Assessment of medicine quality in emerging markets: the changing face of inferior medicines over time / Roger Bate, USA; Lorraine Mooney, UK
The assessment of biosimilarity with SABE and IBE criteria under a switching/alternating design / Aijing Zhang, PhD; Associate Professor Jung-Ying Tzeng; Professor Shein-Chung Chow, PhD, USA (Biosimilarity and Interchangeability)
The naming and labelling of biologicals – a survey of US physicians’ perspectives / Harry L Gewanter, MD, FAAP, FACR; Michael S Reilly, Esq
Bioequivalence study of two formulations of 60 mg daclatasivir in healthy volunteers / Sattam Turky AlGhodyyr, MSc; Mohammad Khalil, Mohammad, R.Ph., PhD; Sanabel Omar Dawabsheh; Mohammad Ali Abu Fara, MD; Majdi Naser Abu Al hajj; Rabab Fayyez Tayyem, PhD
Ocular emulsions and dry eye: a case study of a non-biologic complex drug product delivered to a complex organ to treat a complex disease / Anu Gore, PhD; Mayssa Attar, PhD; Chetan Pujara, PhD; Sesha Neervannan, PhD
Cost-minimization analysis of generic equivalents (bortezomib, decitabine, and capecitabine) in comparison to the originator brand medicines in Columbia / Shyam Akku, MD, India; Amit Garg, MD, India; Suhas Khandarkar, MPharm, India
Generic immonusuppressants comparability studies / Marc Maliepaard, PhD; Professor Hubert G M Leufkens, PharmD, PhD, The Netherlands (Generic Immunosuppressants in Transplantation)
Regulatory Science Ireland: bridging the information gap on biosimilar medicines / Joan O’Callaghan, BSc Pharm, Ireland; Sean Barry, PhD, Ireland; Una Moore, PhD, Ireland; Margaret Bermingham, PhD, Ireland; J Michael Morris, PhD, Ireland; Frank Hallinan, PhD, Ireland; Brendan T Griffin, PhD, Ireland
Pharmacovigilance of biologicals and biosimilars within the hospital: current practices and future challenges / Barbara OM Claus, PharmD, PhD; Tiene Bauters, PharmD, PhD; Annemie Somers, PharmD, PhD; Belgium
Where does the value of ‘value-added’ pharmaceuticals come from? / Fereshteh Barei, PhD
Generic immunosuppression in transplantation: a controversial analysis / Jacques Rottembourg, MD
Patent expiry dates for biologicals: 2016 update / Michelle Derbyshire, PhD, GaBI Online Editor
The role of European Pharmacopoeia monographs in setting quality standards for biotherapeutic products / Emmanuelle Charton, PhD
Generic medicines entry into the Malaysian pharmaceutical market / Omotayo Fatokun, PhD; Professor Mohamed Izham Mohamed Ibrahim, PhD; Professor Mohamed Azmi Hassali, PhD
Overview of the patent expiry of (non-)tyrosine kinase inhibitors approved for clinical use in the EU and USA / Subramanian Venkatesan, MSc, Martine Lamfers, PhD, Sieger Leenstra, MD, PhD, Arnold G. Vulto, PharmD PhD FCP
Data requirements to demonstrate biosimilarity in the EU / Michelle Derbyshire, PhD, GaBI Online Editor
Biosimilar product labels in Europe: what information should they contain? / Alice Rolandini Jensen, MSci, GaBI Journal Editor
Top developments in biosimilars during 2016 / Michelle Derbyshire, PhD, GaBI Online Editor
Abstracted Scientific Content
Effective generics substitution / Maysoon Delahunty, GaBI Journal Editor
Essential information for internists on biologicals and biosimilars / Michelle Derbyshire, PhD, GaBI Online Editor
An empirical study of market-based purchasing policies for generic pharmaceuticals in Sweden / Maysoon Delahunty, GaBI Journal Editor
Strategies used to delay or prevent access to affordable generic drugs in the US / Maysoon Delahunty, GaBI Journal Editor
Effect of naming on pharmacists’ perceptions and dispensing of biosimilars / Michelle Derbyshire, PhD, GaBI Online Editor
Click here for more details on the educational series.
Contact us for an updated list of editorial topics in forthcoming issues.
*Editorial content may differ from final version of manuscript published in print.